Pharmaceuticals

Nuclear Medicine Radioisotopes Market Performance Outlook 2026–2030: Revenue to Hit $12.75 Billion at 7.4% CAGR

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the nuclear medicine radioisotopes market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Nuclear Medicine Radioisotopes Market in 2030?

The nuclear medicine radioisotopes market size has experienced significant growth in recent years. It is projected to expand from $8.85 billion in 2025 to $9.58 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.2%. This historical growth can be attributed to the widespread utilization of technetium-99m in diagnostic imaging, increasing adoption of nuclear cardiology procedures, a rising prevalence of cancer and thyroid disorders, the expansion of hospital-based nuclear medicine departments, and the early clinical success of radioisotope-based therapies.

The nuclear medicine radioisotopes market is set to experience robust expansion in the upcoming years, with its size projected to reach $12.75 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. This anticipated growth during the forecast period can be attributed to factors such as the increasing demand for personalized cancer treatment, the expanding application of lutetium-177 and actinium-225 therapies, the development of PET imaging infrastructure, rising investments in cyclotron and reactor facilities, and the growing adoption of nuclear medicine in emerging economies. Key trends expected over this period include the rising integration of theranostics in oncology care, a growing demand for PET and SPECT imaging procedures, increased use of targeted alpha and beta emitters, the broadening scope of nuclear medicine in cardiology and neurology, and a strengthening focus on domestic radioisotope production.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp

What Drivers Are Influencing Production Trends In The Nuclear Medicine Radioisotopes Market?

An anticipated increase in cardiovascular disease incidence is projected to boost the expansion of the nuclear medicine radioisotope market moving ahead. These conditions encompass a range of ailments impacting the heart and its vascular system. The escalation in cardiovascular disease cases can be attributed to factors such as inactive lifestyles, unhealthy eating patterns, a surge in obesity rates, and an aging demographic. Nuclear medicine radioisotopes play a crucial role in the diagnosis, assessment, and management of cardiovascular conditions, offering precise data on heart function, blood flow, and tissue health, which are vital for accurate identification and successful treatment strategies. An illustrative example comes from January 2024, when the American Heart Association, a US-based non-profit, reported an increase in the age-adjusted death rate from cardiovascular disease, reaching 233.3 per 100,000 in 2024, a 4.0% rise from 224.4 per 100,000 in 2023. Consequently, the growing incidence of cardiovascular diseases is serving as a catalyst for the expansion of the nuclear medicine radioisotope market.

Which Segment Groups Are Influencing The Nuclear Medicine Radioisotopes Market?

The nuclear medicine radioisotopes market covered in this report is segmented –

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types

2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Subsegments:

1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)

2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging

3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)

4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging

5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging

6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment

7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment

8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment

9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

What Upcoming Trends Are Likely To Define The Future Path Of The Nuclear Medicine Radioisotopes Market?

Leading entities within the nuclear medicine radioisotopes market are directing their efforts towards creating cutting-edge solutions, specifically next-generation theranostic radiopharmaceuticals, to improve the accuracy of imaging and the specificity of treatments. These next-generation theranostic radiopharmaceuticals are sophisticated radioactive compounds developed to both identify and accurately treat illnesses by precisely targeting particular cells within the body. An illustrative example occurred in November 2025, when the University of California, a US-based research institution, established a fully autonomous Department of Nuclear Medicine & Theranostics, opting to position nuclear medicine as a distinct entity rather than part of a larger radiology department. This newly formed department is intended to expedite the merger of advanced imaging techniques with targeted radiopharmaceutical therapies. Furthermore, it seeks to bolster research, educational, and clinical initiatives, thereby fostering progress in precision medicine and propelling advancements in theranostic solutions.

Who Are The Top-Performing Companies In The Nuclear Medicine Radioisotopes Market In Recent Years?

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Which Region Currently Holds The Largest Share Of The Nuclear Medicine Radioisotopes Market?

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Nuclear Medicine Radioisotopes Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16132&type=smp

Browse Through More Reports Similar to the Global Nuclear Medicine Radioisotopes Market 2026, By The Business Research Company

Nuclear Medicine Radioisotopes Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Diagnostic Radioisotopes Market Report 2026

https://www.thebusinessresearchcompany.com/report/diagnostic-radioisotopes-global-market-report

Nuclear Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795